X

Trial Profile

A Randomised, Double-Blind Phase II Trial of Topical HDIT101 Versus Placebo in Patients With Chronic Recurrent HSV-1 Infection and Orolabial Lesion

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HDIT-101 (Primary)
Indications Herpes simplex virus type 1 infections
Focus Therapeutic Use
Acronyms MATCH-1
Sponsors Heidelberg ImmunoTherapeutics

Most Recent Events

21 Sep 2023 Status changed from active, no longer recruiting to discontinued for futility in interim analysis.
20 Jul 2023 Planned End Date changed from 1 Apr 2024 to 31 Jul 2023.
26 Jan 2023 Planned End Date changed from 1 Oct 2023 to 1 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com